NeoGenomics, Inc (NEO) Q2 2023 Earnings Call Transcript


NeoGenomics, Inc (NASDAQ:NEO) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET

Company Participants

Kendra Sweeney – Vice President, Investor Relations

Chris Smith – Chief Executive Officer

Jeff Sherman – Chief Financial Officer

Vishal Sikri – President, Advanced Diagnostics

Warren Stone – President, Clinical Services

Melody Harris – President, Enterprise Operations

Conference Call Participants

Dan Brennan – TD Cowen

Alex Nowak – Craig-Hallum Capital Group

David Delahunt – Goldman Sachs

Mark Massaro – BTIG

Tejas Savant – Morgan Stanley

Derik De Bruin – Bank of America

Mike Matson – Needham & Company

Mason Carrico – Stephens

Andrew Cooper – Raymond James

Operator

Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note this call is being recorded, and an audio replay will be available on the company’s website. Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.

Kendra Sweeney

Thank you, Jenny. Good morning everyone and welcome to the NeoGenomics second quarter financial results call. With me today to discuss the results are Chris Smith, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A, including Vishal Sikri, President of Advanced Diagnostics; Warren Stone, President of Clinical Services; and Melody Harris, President of Enterprise Operations. This call is being simultaneously webcast. We will be referring to a slide presentation that has been posted to the Investors tab on our website at ir.neogenomics.com.

Starting on Slide 2. During this call, we will make forward-looking statements regarding our anticipated future performance, such as our operational and financial outlooks and suggestions, our assumptions for that outlook, opportunities, and strategies for our products, and related effects on our financial and operating results. We caution you that such statements reflect our best judgment based



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *